Ward J E, Coles P, Cox H, Eisenhofer G, Angus J A
Baker Medical Research Institute, Prahran, Victoria, Australia.
J Cardiovasc Pharmacol. 1992 Jul;20(1):115-24.
Nebivolol, a chemically novel beta 1-adrenoceptor antagonist, acutely lowers blood pressure in spontaneously hypertensive rats, anaesthetised normotensive dogs, and hypertensive patients. We have investigated the actions of dl-nebivolol in five conscious normotensive rabbits (sham, mean blood pressure (BP) of 82.2 +/- 4.1 mm Hg, mean +/- SEM) and four hypertensive rabbits (renal wrap hypertension) (wrap, mean BP of 117.6 +/- 1.5 mm Hg). Nebivolol (1 mg/kg i.v.) did not significantly lower the BP or heart rate in either group 30 min after injection. In the same rabbits, on another day, after autonomic blockade (mecamylamine), nebivolol (0.1, 0.3, and 1.0 mg/kg i.v.) right shifted the bolus i.v. isoproterenol tachycardia dose-response curves by dose ratios of 5, 18, and 90 in sham rabbits, respectively, and 5, 11, and 23 in wrap rabbits, respectively, indicating significant cardiac beta 1-adrenoceptor antagonism. In guinea pig isolated right atria pretreated with atropine (1 microM) and desipramine (DMI, 0.1 microM), norepinephrine concentration-response curves were antagonised competitively by nebivolol (3-100 nM), giving a pKb of 7.90. In separate atria without DMI pretreatment, neither nebivolol (100 nM) nor propranolol (100 nM) had any significant effect on the increase in the rate of norepinephrine efflux following electrical field stimulation (0.5-2 Hz, 3 min). These findings suggest that at concentrations of nebivolol that show substantial beta 1-adrenoceptor antagonism, there is no evidence of hypotension or bradycardia nor additional effects on cardiac norepinephrine release. Why nebivolol lowers blood pressure in some species but not in the conscious rabbit is not known.
奈必洛尔是一种化学结构新颖的β1肾上腺素能受体拮抗剂,能使自发性高血压大鼠、麻醉的正常血压犬和高血压患者的血压急性降低。我们研究了消旋奈必洛尔对5只清醒正常血压兔(假手术组,平均血压(BP)为82.2±4.1 mmHg,平均值±标准误)和4只高血压兔(肾包裹性高血压)(包裹组,平均BP为117.6±1.5 mmHg)的作用。注射奈必洛尔(1 mg/kg静脉注射)30分钟后,两组的血压或心率均未显著降低。在同一天,对同一批兔子进行自主神经阻断(美加明)后,奈必洛尔(0.1、0.3和1.0 mg/kg静脉注射)使假手术组兔子静脉注射异丙肾上腺素的心动过速剂量反应曲线分别右移5、18和90倍,使包裹组兔子的剂量反应曲线分别右移5、11和23倍,表明存在显著的心脏β1肾上腺素能受体拮抗作用。在用阿托品(1 μM)和地昔帕明(DMI,0.1 μM)预处理的豚鼠离体右心房中,去甲肾上腺素浓度反应曲线被奈必洛尔(3 - 100 nM)竞争性拮抗,pKb为7.90。在未用DMI预处理的单独心房中,奈必洛尔(100 nM)和普萘洛尔(100 nM)对电场刺激(0.5 - 2 Hz,3分钟)后去甲肾上腺素流出速率的增加均无显著影响。这些发现表明,在显示出显著β1肾上腺素能受体拮抗作用的奈必洛尔浓度下,没有低血压或心动过缓的证据,也没有对心脏去甲肾上腺素释放的额外影响。奈必洛尔为何能使某些物种的血压降低而对清醒兔无效尚不清楚。